Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3446432 | 0.90 | L3MBTL1 (0.42) | IDO1TDO2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL13035564 | 0.88 | IDO1 (0.40) | IDO1TDO2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL13035538 | 0.83 | MEN1 (0.32) | ALDH1A1 | |
| SCHEMBL13035533 | 0.83 | RPS6KA1 (0.35) | SMN1; SMN2MAPTCA12CA1CA2 | |
| SCHEMBL13035563 | 0.81 | SYK (0.42) | IDO1TDO2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL3447110 | 0.81 | KDM4E (0.32) | — | |
| SCHEMBL3445785 | 0.81 | NAAA (0.33) | — | |
| SCHEMBL16447119 | 0.80 | NT5E (0.30) | — | |
| SCHEMBL13035397 | 0.79 | PTGDR2 (0.39) | SMN1; SMN2L3MBTL1CASP1ALDH1A1 | |
| SCHEMBL19309521 | 0.78 | PPIA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-05-14 | — | — | US | disclosed |
| US-8895534-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7816344-B2 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | IDO1 1916/4885TDO2 2129/4885LMNA 4338/4885 |
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | IDO1 1916/4885TDO2 2129/4885LMNA 4338/4885 |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | OXA1L, TLR1, OXER1 | IDO1 360/4885TDO2 641/4885LMNA 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.